GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) analogs are increasingly being used in the treatment of type 2 diabetes. It is clear that these drugs lower blood glucose through an increase in insulin secretion and a lowering of glucagon secretion; in addition, they lower body weight and systolic blood pressure and increase heart rate. Using a new monoclonal antibody for immunohistochemistry, we detected GLP-1 receptor (GLP-1R) in important target organs in humans and monkeys. In the pancreas, GLP-1R was predominantly localized in β-cells with a markedly weaker expression in acinar cells. Pancreatic ductal epithelial cells did not express GLP-1R. In the kidney and lung, GLP-1R was exclusively expressed in smooth muscle cells in the walls of arteries and arterioles. In the heart, GLP-1R was localized in myocytes of the sinoatrial node. In the gastrointestinal tract, the highest GLP-1R expression was seen in the Brunner's gland in the duodenum, with lower level expression in parietal cells and smooth muscle cells in the muscularis externa in the stomach and in myenteric plexus neurons throughout the gut. No GLP-1R was seen in primate liver and thyroid. GLP-1R expression seen with immunohistochemistry was confirmed by functional expression using in situ ligand binding with 125I-GLP-1. In conclusion, these results give important new insight into the molecular mode of action of GLP-1 analogs by identifying the exact cellular localization of GLP-1R.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, GLP-1R is present beyond the confines of the pancreas and extends to a multitude of organs and tissues throughout the body. Its extensive distribution and involvement in diverse physiological processes emphasize the important role of GLP-1R beyond the regulation of glucose metabolism.38–40”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [38]
In the citing paper
“Nevertheless, studies using antibodies that appear to be specific for this receptor are consistent with results from gene expression studies, demonstrating staining for the GLP-1 receptor in human and primate kidney in juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“The major site of expression appears to be in the renin-expressing juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“despite only modest expression of the GLP-1 receptor in the kidney”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“In contrast, in primate and human thyroids, GLP-1R has either not been detected (74) or only found in small fractions of healthy C cells (75), and treatment with liraglutide does not stimulate calcitonin secretion (76).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [74]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“This strain of mice is on a C57BL background and is derivedfromthepreviouslydescribedGLP-1Rknockoutstrain(20) custom bred by Novo Nordisk A/S at Taconic.”
MethodBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“In situ ligand binding for functional GLP-1R localization was performed as described previously, apart from the use of (125)IGLP-1 (7–36) (NEX3080; PerkinElmer) instead of (125)I-exendin (9–39) (21, 22).”
MethodSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“GLP-1 has been shown to inhibit gastric acid secretion and gastric motility (36), and these effects fit well with our GLP-1R IHC findings.”
ResultTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 5×
“1284 Pyke et al Immunolocalization of GLP-1R Endocrinology, April 2014, 155(4):1280–1290”
BackgroundInfluentialSelf-citationCentral administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 4×
“The low-level GLP-1R expression in acinar cells reported in this study corresponds well with previous reports using ISLB on normal human pancreas (8, 25).”
BackgroundResultInfluentialWei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
Campos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Cited by
Items 101–200 of 880
Ussher, J. R., Campbell, J. E., Mulvihill, E. E., Baggio, L. L., Bates, H. E., McLean, B. A., Gopal, K., Capozzi, M. E., Yusta, B., Cao, X., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.003 · Cited by 108
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12601 · Cited by 102
“A direct effect may be conceivable, as GLP-1 receptors are present in human and monkey smooth muscle cells of the afferent renal arteriolar wall [26].”
BackgroundLiraglutide for Type 2 diabetes and obesity: a 2015 update
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1054810 · Cited by 101
“In addition, GLP-1 has direct vasodilatory effects [86,87], and GLP-1 receptors have been localized in myocytes of the sinoatrial node in the heart, which may in part explain the increase in heart rate during liraglutide treatment [88].”
BackgroundRisk of pancreatitis in patients treated with incretin-based therapies
Meier, J. J., & Nauck, M. A. (2014) · Diabetologia · doi:10.1007/s00125-014-3231-y · Cited by 101
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
“In mice, reporter gene expression using GLP1R fluorescent labelling localised the GLP-1 receptor to atrial cardiomyocytes (CMs) (Richards et al., 2014), whereas a study in primates and humans limited cardiac GLP-1 receptor expression to the sinoatrial node (Pyke et al., 2014).”
Muzurović, E. M., Volčanšek, Š., Zibar, K., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221146371 · Cited by 126
“Nevertheless, the presence or absence of GLP-1R in hepatocytes is controversial.(34,160,165,166) GLP-1 increases glucose utilization in the liver, skeletal muscle, and AT by inducing glycogen and lipid synthesis independently of insulin level.”
BackgroundSharkovska, Y., Reichetzeder, C., Alter, M., Tsuprykov, O., Bachmann, S., Secher, T., Klein, T., & Hocher, B. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000328 · Cited by 109
“An autoradiographic and in-situ hybridization analysis in both mice and rats localized the renal GLP-1R within the glomerular capillary and arterial walls, and its activation increased the renal blood flow [39–41].”
BackgroundSalvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
“Some studies report expression of GLP-1Rs in VSMCs but not in coronary ECs [222,223].”
BackgroundAntidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
Fisman, E. Z., & Tenenbaum, A. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0294-0 · Cited by 107
“This impact is rooted in the fact that the presence of GLP-1 receptors in human cardiac myocytes has been demonstrated two decades ago [141] and subsequently confirmed in later years [142, 143], boosting the interest of researchers to properly establish the relevance of the gliptin-induced changes in clinical settings.”
BackgroundGlucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Alavi, S. E., Cabot, P. J., & Moyle, P. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00308 · Cited by 95
Gastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology · doi:10.1002/hep.28827 · Cited by 96
“However, we cannot determine whether EX exerts a direct effect on hepatic glucose metabolism independent of the GLP-1 receptor, or whether the incretin’s effect is mediated through activation of the peripheral nervous system, given that GLP-1 receptors are found highly expressed within fibers innervating the portal ve…”
BackgroundYun, C., Yan, S., Liao, B., Ding, Y., Qi, X., Zhao, M., Wang, K., Zhuo, Y., Nie, Q., Ye, C., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01041-8 · Cited by 110
“GLP-1 is considered to be a key molecule connecting host metabolism and reproductive health 16 and is an intestinally derived hypogly-caemia hormone that acts via GLP-1R signalling 39,40 .”
Control of insulin secretion by GLP-1
Jones, B. J., Bloom, S. R., Buenaventura, T., Tomás, A., & Rutter, G. A. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.013 · Cited by 107
Abushamat, L. A., Shah, P. A., Eckel, R. H., Harrison, S. A., & Barb, D. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.01.032 · Cited by 92
Shah, S. J., Sharma, K., Borlaug, B. A., Butler, J., Davies, M., Kitzman, D. W., Petrie, M. C., Verma, S., Patel, S., Chinnakondepalli, K. M., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae322 · Cited by 94
Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1825 · Cited by 94
“receptor expression has been reported in a wide range of rodent and human tissues, including the pancreatic islets, lung, heart, kidney, gastrointestinal tract, pituitary, skin, and several regions of the nervous system (7,8).”
BackgroundAsmar, A., Simonsen, L., Asmar, M., Madsbad, S., Holst, J. J., Frandsen, E., Moro, C., Jonassen, T., & Bülow, J. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00429.2014 · Cited by 93
Seghieri, M., Christensen, A. S., Andersen, A., Solini, A., Knop, F. K., & Vilsbøll, T. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00649 · Cited by 92
Newer GLP-1 receptor agonists and obesity-diabetes
Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 111
Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Paternoster, S., & Falasca, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00584 · Cited by 91
Michos, E. D., Lopez‐Jimenez, F., & Gulati, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029282 · Cited by 90
Ciardullo, S., Muraca, E., Vergani, M., Invernizzi, P., & Perseghin, G. (2023) · Gastroenterology report · doi:10.1093/gastro/goae029 · Cited by 122
“On the other hand, most studies did not identify GLP1 receptors on hepatocytes [52, 53].”
BackgroundPerspectives in GLP-1 Research: New Targets, New Receptors
Cantini, G., Mannucci, E., & Luconi, M. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.017 · Cited by 102
“In addition, GLP-1R-specific expression in sinoatrial node myocytes in humans and primates could explain, at least in part, the increase of heart rate induced by GLP-1RAs, and it could contribute to their hypotensive effect [69].”
BackgroundInteractions between the microbiota and enteric nervous system during gut-brain disorders
Fried, S. G., Wemelle, E., Cani, P. D., & Knauf, C. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108721 · Cited by 102
Glucagon‐like peptide‐1 receptor expression in the human eye
Hebsgaard, J. B., Pyke, C., Yildirim, E., Knudsen, L. B., Heegaard, S., & Kvist, P. H. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13339 · Cited by 88
“GLP-1R expression in tissues of particular interest, such as the pancreas, kidney and thyroid.(10,11) We have now investigated GLP-1R expression in normal human eyes and eyes of patients with advanced stages of proliferative DR (PDR) by IHC with the thoroughly validated monoclonal antibody 3F52.”
MethodSelf-citationA novel mouse model of glucagon‐like peptide‐1 receptor expression: A look at the brain
Graham, D. L., Durai, H. H., Trammell, T. S., Noble, B. L., Mortlock, D. P., Galli, A., & Stanwood, G. D. (2020) · Journal of Comparative Neurology · doi:10.1002/cne.24905 · Cited by 88
“Some efforts offer hope (Pyke et al., 2014), although testing thus far has been limited to peripheral tissues, and such antibodies are not yet commercially available.”
BackgroundGLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.001 · Cited by 104
Gupta, P., Bala, M., Gupta, S. K., Dua, A., Dabur, R., Injeti, E. R., & Mittal, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.029 · Cited by 101
Steinberg, W. M., Buse, J. B., Ghorbani, M. L. M., Ørsted, D. D., Nauck, M. A., the LEADER Steering Committee, & on behalf of the LEADER Trial Investigators (2017) · Diabetes Care · doi:10.2337/dc16-2747 · Cited by 87
“whether human pancreatic acinar cells express GLP-1 receptors (19,20), recent animal studies indicate that pancreatic acinar cells have GLP-1 receptors that, when stimulated, increase the production and secretion of pancreatic enzymes (20).”
Biological Control of Pest and Vector Insects
Shields, V. D. C. (2017) · InTech eBooks · doi:10.5772/63274 · Cited by 91
Cyclic tailor-made amino acids in the design of modern pharmaceuticals
Liu, J., Han, J., Izawa, K., Sato, T., White, S., Meanwell, N. A., & Soloshonok, V. A. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112736 · Cited by 88
Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node
Lubberding, A. F., Veedfald, S., Achter, J. S., Nissen, S. D., Soattin, L., Sorrentino, A., Vega, E. T., Linz, B., Eggertsen, C. H. E., Mulvey, J., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae120 · Cited by 84
“42 However, Wallner et al .”
McLean, B. A., Wong, C. K., Kaur, K. D., Seeley, R. J., & Drucker, D. J. (2021) · JCI Insight · doi:10.1172/jci.insight.153732 · Cited by 84
“Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases.”
BackgroundWang, D., Ma, Y., Tong, X., Zhang, Y., & Fan, H. S. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00196 · Cited by 92
“GLP-1 receptor, a G protein coupled receptor, predominantly localized in β-cells of pancreas and smooth muscle cells of arteries and arterioles in kidney and lung, is mainly used as the target for anti-diabetic drugs (56).”
BackgroundMøllerhøj, M. B., Veidal, S. S., Thrane, K. T., Oró, D., Overgaard, A., Salinas, C. G., Madsen, M. R., Pfisterer, L., Vyberg, M., Simon, E., et al. (2022) · Clinical and Translational Science · doi:10.1111/cts.13235 · Cited by 82
Zhang, L., Pang, X.-F., Bai, F., Wang, N.-P., Shah, A., McKallip, R. J., Li, X., Wang, X., & Zhao, Z. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6592-7 · Cited by 84
“Native GLP-1 receptor has been identified in the endocardium, smooth muscle cells and cardiomyocytes [40].”
BackgroundCrosstalk between gut microbiota and antidiabetic drug action
Kyriachenko, Y., Falalyeyeva, T. M., Korotkyi, O., Molochek, N., & Kobyliak, N. M. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i3.154 · Cited by 85
miR-204 Controls Glucagon-Like Peptide 1 Receptor Expression and Agonist Function
Jo, S., Chen, J., Xu, G., Grayson, T. B., Thielen, L. A., & Shalev, A. (2018) · Diabetes · doi:10.2337/db17-0506 · Cited by 80
“These side effects are not necessarily surprising given the fact that GLP1R is expressed not only in pancreatic b-cells but also in in the exocrine pancreas, stomach, and brain (28,29).”
BackgroundThe effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Neves, J. S., Vasques‐Nóvoa, F., Borges‐Canha, M., Leite, A. R., Sharma, A., Carvalho, D., Packer, M., Zannad, F., Leite‐Moreira, A., & Ferreira, J. P. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14862 · Cited by 80
“GLP-1 receptors are expressed in cardiomyocytes and sinoatrial node cells, signalling through a cAMP-dependent pathway.(13) Preclinical data have already shown an increase in cardiac intracellular cAMP levels with GLP-1RA treatment.”
BackgroundDetka, J., & Głombik, K. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00274-8 · Cited by 79
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
He, Y., Chen, Y., Qian, S., van Der Merwe, S., Dhar, D., Brenner, D. A., & Tacke, F. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01307-5 · Cited by 81
The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
Drucker, D. J. (2018) · Diabetes · doi:10.2337/dbi18-0008 · Cited by 78
“Within the mouse, rat, and human kidney, the GLP1R has been localized to a few scattered VSMs (34,45,46), and in some instances, colocalized with juxtaglomerular cells.”
BackgroundInfluentialCardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review
Boyle, J. G., Livingstone, R., & Petrie, J. R. (2018) · Clinical Science · doi:10.1042/cs20171299 · Cited by 78
“GLP-1 receptors are not widely found in the CV system (except in the sino-atrial node) [33].”
BackgroundHuang, Z., Liu, L., Zhang, J., Conde, K., Phansalkar, J., Li, Z., Yao, L., Xu, Z., Wang, W., Zhou, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn5345 · Cited by 78
Siraj, M. A., Mundil, D., Beca, S., Momen, A., Shikatani, E. A., Afroze, T., Sun, X., Liu, Y., Ghaffari, S., Lee, W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci99934 · Cited by 78
“It is tempting to speculate that this apparent loss of benefit in patients with more advanced HF may be the result of increases in HR caused by activation of sinoatrial node (SAN) GLP-1Rs (64, 65), which could be mitigated with an agent such as GLP-1(28–36) that retains cardiac and vascular protection of GLP-1, withou…”
BackgroundTherapeutic horizons in metabolic dysfunction–associated steatohepatitis
Newsome, P. N., & Loomba, R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186425 · Cited by 90
“The balance of evidence would suggest that, in the absence of hepatic GLP-1 receptors (11), any effect on fibrosis is likely to be largely indirect and mediated through a reduction in the upstream drivers of the condition.”
Nakatani, Y., Kawabe, A., Matsumura, M., Aso, Y., Yasu, T., Banba, N., & Nakamoto, T. (2016) · Diabetes Care · doi:10.2337/dc15-1437 · Cited by 77
Decara, J., Rivera, P., Arrabal, S., Vargas, A., Serrano, A., Pavón, F. J., Dieguez, C., Nogueiras, R., Rodríguez de Fonseca, F., & Suárez, J. (2018) · Acta Physiologica · doi:10.1111/apha.13008 · Cited by 76
Steinberg, W. M., Rosenstock, J., Wadden, T. A., Donsmark, M., Jensen, C. B., & DeVries, J. H. (2017) · Diabetes Care · doi:10.2337/dc16-2684 · Cited by 76
“GLP-1 receptors are weakly expressed on the acinar cells in the human pancreas (26), and inmice, short-termGLP-1 receptor activation leads to increased acinar cell amylase secretion (27).”
Actions of glucagon‐like peptide‐1 receptor ligands in the gut
Holst, J. J., Andersen, D. B., & Grunddal, K. V. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15611 · Cited by 73
Wang, J., & Kim, C. H. (2022) · Endocrine Research · doi:10.1080/07435800.2021.1955255 · Cited by 74
“Moreover, GLP-1 receptors are also expressed at high levels in various tumors, such as pheochromocytoma, medullary thyroid carcinoma, meningioma, embryonic tumors, and prostate carcinomas.(2,4,5) Interestingly, in vitro studies and animal models showed that GLP-1 receptor activation could promote or inhibit tumor grow…”
Backgroundde Mesquita, F. C., Guixé-Muntet, S., Fernández-Iglesias, A., Maeso-Díaz, R., Vila, S., Hide, D., Ortega-Ribera, M., Rosa, J. L., García-Pagán, J. C., Bosch, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02866-y · Cited by 74
Time course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment
von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F., & Rossing, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12594 · Cited by 73
Ribeiro-Silva, J. C., Tavares, C. A. M., & Girardi, A. C. C. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102355 · Cited by 71
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 77
“The bene fi cial effect of GLP-1 receptor agonists on the liver are mediated by multiple pathways, but apparently not by direct effects on hepatocytes, which lack GLP-1 receptors (60).”
BackgroundExenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium
Wallner, M., Kolesnik, E., Ablasser, K., Khafaga, M., Wakula, P., Ljubojević-Holzer, S., Thon-Gutschi, E., Sourij, H., Kapl, M., Edmunds, N. J., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.09.018 · Cited by 75
Mensberg, P., Nyby, S., Jørgensen, P. G., Storgaard, H., Jensen, M. T., Sivertsen, J., Holst, J. J., Kiens, B., Richter, E. A., Knop, F. K., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12797 · Cited by 69
Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation
Hviid, A. V. R., & Sørensen, C. M. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00280.2019 · Cited by 69
“(63) 2014 Monkey and human (tissue slices) IHC and ISLB Monoclonal antibody mAb 3F52 IHC and ISLB: GLP-1R staining in the preglomerular vascular compartment Jensen et al.”
BackgroundMethodGLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
Monti, G., Gomes Moreira, D., Richner, M., Mutsaers, H. A. M., Ferreira, N., & Jan, A. (2022) · Cells · doi:10.3390/cells11132023 · Cited by 68
Ali, S., Ussher, J. R., Baggio, L. L., Kabir, M. G., Charron, M. J., Ilkayeva, O., Newgard, C. B., & Drucker, D. J. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.11.005 · Cited by 69
“Glucagon impairs outcomes during experimental MI in a p38 MAPK-dependent manner As recent studies of the related Glp1r revealed issues with receptor localization and surprising chamber-specific receptor expression [22,30,31], we first assessed Gcgr expression in the mouse heart using both regular PCR and primers corre…”
Methodvon Scholten, B. J., Hansen, T. W., Goetze, J. P., Persson, F., & Rossing, P. R. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.04.004 · Cited by 72
“The heart rate-increasing effect of GLP-1 treatment has been well described and discussed, and a recent study demonstrated presence of GLP-1 receptors in the sinoatrial node in the heart (Pyke et al., 2014).”
BackgroundBifari, F., Manfrini, R., Dei Cas, M., Berra, C., Siano, M., Zuin, M., Paroni, R., & Folli, F. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 69
Overcoming the challenges of tissue delivery for oligonucleotide therapeutics
Gökirmak, T., Nikan, M., Wiechmann, S., Prakash, T. P., Tanowitz, M., & Seth, P. P. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.04.010 · Cited by 73
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Moschovaki Filippidou, F., Kirsch, A. H., Thelen, M., Kétszeri, M., Artinger, K., Aringer, I., Schabhüttl, C., Mooslechner, A. A., Frauscher, B., Pollheimer, M., et al. (2020) · The American Journal of Pathology · doi:10.1016/j.ajpath.2019.10.008 · Cited by 66
Zhou, L., Qu, H., Yang, L., & Shou, L. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01500-5 · Cited by 66
“Glucagon-like peptide 1 is one of the most thoroughly studied incretins and its receptors are widely expressed in pancreas, gastrointestinal tract, heart, and even brain [12].”
BackgroundFerreira, J. P., Saraiva, F., Sharma, A., Vasques‐Nóvoa, F., Angélico‐Gonçalves, A., Leite, A. R., Borges‐Canha, M., Carvalho, D., Packer, M., Zannad, F., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14997 · Cited by 65
“CKD 2307 (25) 939 (29) 3191 (22) 2157 (23) 856 (27) 2199 (22) 408 (10)”
Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases
Chen, S., Chuang, Y., Lin, T., & Yang, J. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175439 · Cited by 73
Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 65
“within the monkey pulmonary artery (63).”
MethodInfluentialQuast, D. R., Schenker, N., Menge, B. A., Nauck, M. A., Kapitza, C., & Meier, J. J. (2020) · Diabetes Care · doi:10.2337/dc20-0720 · Cited by 64
“with a reduction in gastrin secretion as recently indicated (28), as well as with the expression of GLP-1 receptors on parietal cells (29).”
BackgroundKidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities
Patera, F., Gatticchi, L., Cellini, B., Chiasserini, D., & Reboldi, G. (2024) · Biomolecules · doi:10.3390/biom14010137 · Cited by 78
“GLP-1R is expressed in the kidneys across different cell types [63], and its expression is lower in DKD patients [64].”
BackgroundPotential side effects to GLP-1 agonists: understanding their safety and tolerability
Consoli, A., & Formoso, G. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 63
“An extensive validation of a monoclonal GLP-1R antibody for immunohistochemistry in primate tissues was recently published [5].”
BackgroundMethodInfluentialLocalization of Glucagon-Like Peptide-2 Receptor Expression in the Mouse
Yusta, B., Matthews, D., Koehler, J. A., Pujadas, G., Kaur, K. D., & Drucker, D. J. (2019) · Endocrinology · doi:10.1210/en.2019-00398 · Cited by 62
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12985 · Cited by 62
“The study that used the most extensively validated monoclonal antibody for immunohistochemical assessments to date was unable to detect the presence of GLP-1 receptors in monkey and human proximal tubules, 33 calling direct effects of lixisenatide on tubular sodium handling somewhat into question.”
GLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 61
“127 128 A recent study has demonstrated the absence of the GLP-1R on human pancreatic ductal cells, 10 which contradicts the hypothesis that GLP-1R activation leads to ductal cell proliferation.”
BackgroundEfficacy and safety of semaglutide for weight management: evidence from the STEP program
Amaro, A., Sugimoto, D., & Wharton, S. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2147326 · Cited by 60
Levy, S. M., Attia, A. S., Elshazli, R. M., Abdelmaksoud, A., Tatum, D. M., Aiash, H., & Toraih, E. A. (2024) · Cancers · doi:10.3390/cancers17010078 · Cited by 72
“The widespread expression of GLP-1 receptors in various tissues, including the gastrointestinal tract, pancreatic islets, thyroid gland, kidney, heart, lungs, and central nervous system [8,9], suggests a broader physiological role beyond metabolic regulation [10,11].”
Farokhnia, M., Tazare, J., Pince, C. L., Bruns, N., Gray, J. C., Re, V. L., Fiellin, D. A., Kranzler, H. R., Koob, G. F., Justice, A. C., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci188314 · Cited by 72
Smits, M. M., Muskiet, M. H. A., Tonneijck, L., Hoekstra, T., Kramer, M. H. H., Diamant, M., & van Raalte, D. H. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12843 · Cited by 60
Xiao, C., Dash, S., Morgantini, C., Adeli, K., & Lewis, G. F. (2015) · Diabetes · doi:10.2337/db14-1706 · Cited by 60
“This might be due to the lack of GLP-1R expression in the liver (58).”
BackgroundThomas, M. C., Coughlan, M. T., & Cooper, M. E. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.004 · Cited by 56
Liddle, R. A. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.01.006 · Cited by 69
Asmar, A., Cramon, P. K., Simonsen, L., Asmar, M., Sorensen, C. M., Madsbad, S., Moro, C., Hartmann, B., Jensen, B. L., Holst, J. J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00004 · Cited by 56
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 69
Tonneijck, L., Muskiet, M. H. A., Blijdorp, C. J., Smits, M. M., Twisk, J. W., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., Hoorn, E. J., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00432.2018 · Cited by 57
Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia
Adiels, M., Taskinen, M., Björnson, E., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Sihlbom, C., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13744 · Cited by 55
“probable as several studies have failed to confirm the expression of the canonical GLP-1R in hepatocytes.(30,53,54) Therefore, many actions”
BackgroundZavattaro, M., Caputo, M., Samà, M. T., Mele, C., Chasseur, L., Marzullo, P., Pagano, L., Mauri, M. G., Ponziani, M. C., Aimaretti, G., et al. (2015) · Endocrine · doi:10.1007/s12020-014-0519-0 · Cited by 64
Billah, M., Ridiandries, A., Allahwala, U. K., Mudaliar, H., Dona, A. C., Hunyor, S. N., Khachigian, L. M., & Bhindi, R. (2019) · Oncotarget · doi:10.18632/oncotarget.26537 · Cited by 63
“Basalay and colleagues demonstrated that RIPC conferred cardioprotection by GLP-1R activation and involves M3 muscarinic receptor dependent mechanism [150].”
BackgroundInfluentialElbassuoni, E. A., & Ahmed, R. F. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104583 · Cited by 54
GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
Li, Q.-X., Gao, H., Guo, Y.-X., Wang, B.-Y., Hua, R.-X., Gao, L., Shang, H.-W., Lu, X., & Xu, J.-D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721198 · Cited by 56
Furuhashi, M., Hiramitsu, S., Mita, T., Fuseya, T., Ishimura, S., Omori, A., Matsumoto, M., Watanabe, Y. S., Hoshina, K., Tanaka, M., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m059469 · Cited by 60
Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
Skow, M. A., Bergmann, N. C., & Knop, F. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12685 · Cited by 56
“The GIPR and the GLP-1R are widely expressed; the GIPR has been observed in the pancreas, adipose tissue, gut, heart, pituitary gland, adrenal cortex and the brain [10], and the GLP-1R has been observed in the pancreas, heart, lungs, kidneys, stomach and enteric neurons as well as in the central nervous system [11].”
BackgroundNomoto, H., Miyoshi, H., Furumoto, T., Oba, K., Tsutsui, H., Inoue, A., Atsumi, T., Manda, N., Kurihara, Y., Aoki, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164255 · Cited by 58
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Self-citationGlucagon‐like peptide‐1 receptor is expressed in human and rodent testis
Caltabiano, R., Condorelli, D. F., Panza, S., Boitani, C., Musso, N., Ježek, D., Memeo, L., Colarossi, L., Rago, V., Mularoni, V., et al. (2020) · Andrology · doi:10.1111/andr.12871 · Cited by 64
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure
Ferreira, J. P., Sharma, A., Butler, J., Packer, M., Zannad, F., Vasques-Nóvoa, F., Leite-Moreira, A., & Neves, J. S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad398 · Cited by 54
Andersen, D. B., Grunddal, K. V., Pedersen, J., Kuhre, R. E., Lund, M. L., Holst, J. J., & Ørskov, C. (2021) · Endocrinology · doi:10.1210/endocr/bqaa246 · Cited by 54
Self-citationVergès, B., Duvillard, L., Pais de Barros, J. P., Bouillet, B., Baillot-Rudoni, S., Rouland, A., Petit, J. M., Degrace, P., & Demizieux, L. (2021) · Diabetes Care · doi:10.2337/dc20-1843 · Cited by 54
Kumarathurai, P., Anholm, C., Nielsen, O. W., Kristiansen, O. P., Mølvig, J., Madsbad, S., Haugaard, S. B., & Sajadieh, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0425-2 · Cited by 54
Metadata
- Authors
- Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Department of Diabetes Structural Biology (S.R.-R.), Novo Nordisk, 2880 Bagsværd, Denmark
- Rigshospitalet (DK)
- Corresponding author
- Knudsen, Lotte Bjerre
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2014-04-01
- Volume
- 155
- Issue
- 4
- Pages
- 1280-1290
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1979288606
- Cited by
- 876
- References
- 37
- Citations by year
- 2026: 99 · 2025: 91 · 2024: 103 · 2023: 56 · 2022: 70 · 2021: 64 · 2020: 64 · 2019: 57 · 2018: 60 · 2017: 64 · 2016: 61 · 2015: 58 · 2014: 27
- FWCI
- 56.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Endocrinology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor, glucagon-like peptide-1, receptor localization, type 2 diabetes, GLP-1 analogues, pancreatic beta cells, sinoatrial node, Brunner's glands, myenteric neurons, smooth muscle cells, kidney, heart, gastrointestinal tract, receptor expression
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Insulin Secretion, Animals, Haplorhini, Antibodies, Monoclonal, Blood Pressure, Body Weight, Cell Line, Duodenum, Glucagon, Cricetinae, Heart Rate, Humans, Insulin, Ligands, Mice, Inbred C57BL, Peptides, Protein Binding, Tissue Distribution, Transfection, Venoms, Receptors, Glucagon, Mice, Knockout, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.